

# MARKET REPORT



## KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

## Summary

This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA).

The briefing includes analysis of KOL opinion on the following topic areas -

- Current or anticipated future use of sarilumab in RA
- Current use of tocilizumab in RA
- Expected future change to sarilumab & tocilizumab use
- Comparison of sarilumab & tocilizumab clinical profile in RA
- Non-clinical differentiating factors between sarilumab & tocilizumab
- Impact of and factors contributing to sarilumab discontinuation in RA
- IL-6 inhibitors vs. JAK inhibitors in RA
- KOL awareness of olokizumab currently in development for RA

## Key Highlights

- Majority of US but not EU patients have access to sarilumab, with KOLs primarily positioning sarilumab in MTX-IR patients or after anti-TNFs
- Most KOLs position tocilizumab after anti-TNFs, partly due to payer pressure, with first-line use possible in MTX-IR or ineligible patients
- In the next 12 months, most KOLs expect an increase in use of sarilumab, and a reduction in use of tocilizumab.

## Scope

- The briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based
- Interviews performed in December 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes

- Summary of KOL reporting trends  
<https://www.bioportfolio.co.uk/product/224124>  
[reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) to order

- Insight from Sociable Pharma's analysts.

#### Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "IL-6 inhibitors in Rheumatoid Arthritis"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

#### Additional Details

**Publisher** : Global Data  
**Reference** : GDHC010SP  
**Number of Pages** : 29  
**Report Format** : PDF  
**Publisher Information** :



**GlobalData** »

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis [Report Updated: 01-02-2018]

- Table of ContentsExecutive SummaryBackgroundResearch Panel CompositionResults & ImplicationsAppendix

# How to Buy...

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis [Report Updated: 01-02-2018]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/224124>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.